Last update: June 30, 2015

Oxymetazoline

Low Risk probable for breastfeeding


Moderately safe.
Mild risk possible. Follow up recommended.
Read the Comment.

Sympathomimetic drug that is topically used for treatment of nose or the eye.

A fecha de última actualización no encontramos datos publicados en relación con la lactancia.

A small dose together with a low plama level of most nasal and ophthalmologic compounds make that a significant excretion into breast milk would be unlikely.

Avoid over dosage and do not use it for longer than 3 days: as any other adrenergic-agonist drug, when absorbed, it may be a cause of side effects (vascular hyper-hypotension, irritability, heart arrhythmia) on both the mother and the infant.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Oxymetazoline is also known as


Oxymetazoline in other languages or writings:

Pharmacokinetics

Variable Value Unit
Molecular weight 297 daltons
T1/2 5 - 8 hours

References

  1. Anderson PO. Decongestants and milk production. J Hum Lact. 2000 Abstract
  2. Nice FJ, Snyder JL, Kotansky BC. Breastfeeding and over-the-counter medications. J Hum Lact. 2000 Abstract

Total visits

60,837

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM